FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, October 18th. The stock was sold at an average price of $55.42, for a total transaction of $221,680.00. Following the sale, the director now directly owns 27,700 shares of the company’s stock, valued at approximately $1,535,134. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Kalevi Kurkijarvi also recently made the following trade(s):
- On Monday, September 17th, Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock. The stock was sold at an average price of $58.86, for a total transaction of $235,440.00.
- On Thursday, August 16th, Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock. The stock was sold at an average price of $60.28, for a total transaction of $241,120.00.
NASDAQ:FGEN traded down $1.73 on Friday, hitting $52.90. The company had a trading volume of 904,300 shares, compared to its average volume of 507,912. The company has a market cap of $4.70 billion, a price-to-earnings ratio of -31.75 and a beta of 1.81. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.95 and a quick ratio of 7.95. FibroGen Inc has a 52 week low of $40.74 and a 52 week high of $68.55.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.31. The business had revenue of $43.95 million during the quarter, compared to the consensus estimate of $28.70 million. FibroGen had a negative net margin of 85.59% and a negative return on equity of 22.60%. As a group, analysts expect that FibroGen Inc will post -1.05 EPS for the current year.
A number of analysts have recently weighed in on the stock. Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a report on Wednesday. Leerink Swann set a $84.00 price target on shares of FibroGen and gave the stock a “buy” rating in a report on Monday. BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 9th. ValuEngine downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Finally, Citigroup downgraded shares of FibroGen from a “buy” rating to a “hold” rating and set a $71.00 price objective for the company. in a research note on Wednesday, August 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. FibroGen currently has a consensus rating of “Buy” and an average target price of $72.25.
A number of large investors have recently modified their holdings of FGEN. FMR LLC lifted its stake in FibroGen by 23.8% in the 2nd quarter. FMR LLC now owns 8,463,528 shares of the biopharmaceutical company’s stock valued at $529,817,000 after purchasing an additional 1,624,749 shares during the last quarter. PointState Capital LP lifted its stake in FibroGen by 92.0% in the 2nd quarter. PointState Capital LP now owns 810,200 shares of the biopharmaceutical company’s stock valued at $50,719,000 after purchasing an additional 388,300 shares during the last quarter. Emerald Advisers Inc. PA bought a new position in FibroGen in the 2nd quarter valued at approximately $22,954,000. Emerald Mutual Fund Advisers Trust bought a new position in FibroGen in the 2nd quarter valued at approximately $20,002,000. Finally, BlackRock Inc. lifted its stake in FibroGen by 4.6% in the 2nd quarter. BlackRock Inc. now owns 6,182,657 shares of the biopharmaceutical company’s stock valued at $387,037,000 after purchasing an additional 271,981 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.